{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-038744","form_type":"8-K","ticker":"IMNM","cik":"0001472012","company_name":"Immunome Inc.","filed_at":"2024-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.269033+00:00","generated_at":"2026-06-04T07:48:26.163903+00:00","sec_items":["2.01","1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immunome completes acquisition of Ayala's AL102 Phase 3 desmoid tumor asset for $20M cash + stock","bullets":["Acquisition of AL102 (Phase 3 gamma secretase inhibitor) and AL101; upfront $20M cash and 2,175,489 shares to Ayala.","Potential milestone payments up to $37.5M upon development and commercial milestones.","BMS license assumed: up to $142M clinical/regulatory milestones + $50M commercial milestones per product; royalties high single to low teen % on net sales.","CEO states AL102 may establish new standard of care for desmoid tumors; preclinical programs advancing to Phase 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-038744","json":"https://secwatch.observer/filing/0001104659-24-038744.json","markdown":"https://secwatch.observer/filing/0001104659-24-038744.md","text":"https://secwatch.observer/filing/0001104659-24-038744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/0001104659-24-038744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/tm249326d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T07:48:26.163903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6587053eb08d95dd7fa78d922d36a2275bd209f1","claim":"Immunome Inc. completed an acquisition involving Ayala Pharmaceuticals, Inc. for $20.0 million in cash (closed 2024-03-25).","evidence_excerpt":"by reference. Item 2.01 Completion of Acquisition or Disposition of Assets Pursuant to the terms of the Asset Purchase Agreement, Immunome (i) paid an upfront purchase price of $20.0 million in cash to Ayala, less certain adjustments, (ii) issued Ayala 2 ,175,489 shares of Immunome’s common stock (the “Shares”), (iii) assumed specified liabilities from Ayala, and","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/0001104659-24-038744-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Ayala Pharmaceuticals, Inc."},{"label":"Consideration","value":"$20.0 million in cash"},{"label":"Closing","value":"2024-03-25"}],"fact_type":"ma_transaction"},{"claim_id":"019d314867aba7dbf50d30824ba07abcf68cb802","claim":"Immunome Inc. entered into BMS License with Bristol-Myers Squibb Company valued at up to approximately $142 million.","evidence_excerpt":"In November 2017, Ayala entered into a License Agreement with Bristol-Myers Squibb Company (“BMS”), as amended by that certain First Amendment to License Agreement dated as of May 4, 2020 (the “BMS License”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1472012/000110465924038744/0001104659-24-038744-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Value","value":"up to approximately $142 million"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}